drugset

drugset / Trial / NCT04453111

Efficacy of Bone-marrow-derived and Placenta-derived Multipotent Mesenchymal Stem / Stromal Cells for Osteoarthritis

NCT04453111 ↗

Phase 1/2 Unknown 45 enrolled Institute of Cell Therapy Kyiv City Clinical Hospital № 6 · collab The Institute of Traumatology and Orthopedics of NAMS of Ukraine · collab

Non-randomizedParallel-groupOpen-labelTreatment

Summary

To define the clinical effects of intra-articular transplantation of bone-marrow-derived (BM-MMSCs) and placenta-derived multipotent mesenchymal stem / stromal cells (P-MMSCs) for knee osteoarthritis.

Timeline

Start: 2020-01-02
Primary completion: 2021-08
Completion: 2021-10

Publications

Holiuk Y, Birsa R, Bukreieva T, Nemtinov P, Kyryk V, Ustymenko A, Mazevych V, Sokolov M, Lobyntseva G, Shablii V. Effectiveness and safety of multiple injections of human placenta-derived MSCs for knee osteoarthritis: a nonrandomized phase I trial. BMC Musculoskelet Disord. 2025 Apr 26;26(1):418. doi: 10.1186/s12891-025-08664-2.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bone marrow-derived MMSCs	Unknown	2e+07 cells	Intrathecal
Subject	Placenta-derived MMSCs	Unknown	2e+07 cells	Intrathecal
Background	Hyaluronic Acid	Other / unclassified	20 mg	Intrathecal

Indications